Insulin aspart biosimilar (Sanofi)
门冬胰岛素生物类似药（赛诺菲）
Report date: 2025/02/27 16:12:25
Base Information
Drug NameInsulin aspart biosimilar (Sanofi)
Drug Alias Name +[7]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved Indications
Approved Indications in ChinaN/A
Original Approved Country/Territory
Original Approved Date2020/06/25
Country/Territory
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A
Develop Information
Active CompaniesSanofiSanofi-Aventis U.S. LlcSanofi Winthrop Industrie SA
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC Code
Related LinksN/A